2.80 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||2.75 x 1200|
|Ask||3.05 x 800|
|Day's Range||2.78 - 2.87|
|52 Week Range||2.27 - 6.69|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 20) Avanos Medical Inc (NYSE: AVNS ) Becton Dickinson and Co (NYSE: ...
Novan Inc (NASDAQ: NOVN) shares were advancing strongly Monday after the announcement of positive results for its pipeline candidate SB414. Novan said its SB414 — a nitric oxide-releasing cream product candidate which is being evaluated for atopic dermatitis and psoriasis — produced positive results in two complementary Phase 1b clinical trials. Clinical efficacy measures based on the trials were found to be highly correlated with critical and disease-relevant biomarker changes, the company said.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced an update on the SB414 nitric oxide-releasing cream product candidate and its application to two therapeutic indications: atopic dermatitis and psoriasis. Based on results of two complementary Phase 1b clinical trials with SB414 in patients with psoriasis and atopic dermatitis, Novan intends to advance the development of SB414 as a treatment for atopic dermatitis and conduct additional exploratory trials in psoriasis and acne rosacea.
A newly implemented stockholder return plan at Morrisville-based Novan is targeting share price goals as well as $25 million and $50 million bonus pools.
Novan, Inc. ("the Company" or "Novan") (NOVN) today provided a comprehensive business update in its Form 10-Q for the second quarter of 2018 and announced that it has implemented the Tangible Stockholder Return Plan (the “Performance Plan”). The Performance Plan is a performance-based incentive compensation plan designed to directly align the long-term interests of Novan’s employees, including executive officers, with the interests of Novan’s stockholders.
Novartis’ then-CEO sent ideas to lower drug prices to Michael Cohen — proposals that later appeared in President Donald Trump’s drug pricing plan.
Assessing Novan Inc’s (NASDAQ:NOVN) past track record of performance is a valuable exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, whichRead More...
Michael Avenatti, the lawyer for porn star Stormy Daniels, claimed Tuesday that President Donald Trump's personal attorney Michael Cohen received about $500,000 from a Russian oligarch after the 2016 presidential election. The oligarch Viktor Vekselberg, has close ties to Russian leader Vladimir Putin, and was stopped at a New York-area airport in recent months by investigators working for special counsel Robert Mueller. Cohen paid Daniels $130,000 on the eve of the election in exchange for what she says was her silence about an affair with Trump in 2006.
Morrisville-based Novan has made its interim CEO Kelly Martin permanent, while it looks to a big third quarter for its acne drug.
Novan Inc’s (NASDAQ:NOVN) latest earnings update in December 2017 revealed that losses became smaller relative to the prrior year’s level as a result of recent tailwinds Below, I’ve laid outRead More...
Major figures in business, economics and politics spoke with CNBC at the China Development Forum in Beijing on Sunday.
Novartis and Science 37 commit to launch up to 10 trials with increasing decentralization over three years, scaling to "site-less" model Agreement builds on our long-standing investment in ...
Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), is the only therapy recommended by the guideline for patients unresponsive to antihistamines ...
Shareholders approve 21 st consecutive dividend increase to CHF 2.80 (+2%) per share for 2017; representing a 3.6% yield and approximately 67% payout of free cash flow Dr. Joerg Reinhardt confirmed by ...
Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis` leadership in biomedical ...
Ultibro ® Breezhaler ® provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo CLAIM is the first study to investigate the effect ...